News
News Center
Jiuzhitang's stem-cell drug R&D and production base is expected to be operational by 2019.
来源：China.org
2018-09-15
China Net Finance, September 17 (Reporter Du Ding): Jiuzhitang is making a strategic move into the research, clinical development, and industrialization of stem-cell therapies. Recently, Jiuzhitang’s newly established Jiuzhitang Yonghe Qihang Fund signed an investment agreement with U.S.-based Stemedica Cell Technologies Inc. Through this collaboration, Jiuzhitang will introduce advanced stem-cell production technologies and a robust manufacturing platform, aiming to build a commercial-grade stem-cell production facility meeting both U.S. and EU cGMP standards within three to five years at the Beijing Daxing Biomedical Industry Base.
Li Zhenguo, Chairman of Jiuzhitang, stated that the intrinsic value of traditional Chinese medicine remains largely untapped. By entering the stem-cell field this time, the company aims to leverage its strong advantages in the Chinese medicinal industry while capitalizing on global advancements in stem-cell technology. This strategic move seeks to seamlessly integrate China’s time-honored traditional medicine with cutting-edge stem-cell biotechnology, paving the way for an innovative growth path tailored specifically for a century-old Chinese pharmaceutical enterprise. "Our entry into the stem-cell sector is firmly rooted in the goal of turning cells into medicines. Once we’ve clearly defined our positioning, we’ll begin the global search for qualified and capable partners," Li added.
Li Zhenguo explained that Stemedica, a U.S.-based company, is the first U.S. pharmaceutical firm approved to conduct clinical research using stem cells for Alzheimer's treatment. It is also one of only a handful of U.S. biotech companies certified by the FDA to carry out stem-cell drug trials, and one of the world’s few enterprises capable of producing both human bone marrow mesenchymal stem cells and human neural stem cells.
According to reports, to accelerate the R&D process and gain a competitive edge in China's stem-cell pharmaceutical market, the Yonghe Qihang Fund has invested in the U.S.-based company Stemedica. Simultaneously, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. has been established as the sole Chinese partner entrusted with taking over Stemedica's cutting-edge stem-cell technology from the U.S.
Jiuzhitang (Meike) has achieved world-leading scalability in stem cell production by introducing Stemedica Corporation's globally advanced stem cell manufacturing technology and preparation platform from the U.S., effectively addressing a critical technical hurdle in turning stem cells into viable pharmaceutical products. Currently, the company is constructing an allogeneic stem cell production facility in Beijing’s Daxing District, designed to meet both U.S. and EU cGMP standards. This state-of-the-art facility will be dedicated to the production of human bone marrow-derived mesenchymal stem cells and neural stem cells. The facility will span a total area of 4,500 square meters and is expected to become operational in 2019.
Data shows that among U.S.-listed companies on the Nasdaq, the market capitalization associated with stem cell concept stocks already exceeds $30 billion. By 2020, the global stem cell market is projected to reach $400 billion, while China's stem cell market is expected to grow to as much as 120 billion RMB.
Next:
Related News
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy